MedPath

The effect of combination of valproic acid and anti-tumor drug on pancreatic and biliary cancer

Phase 1
Conditions
unresectable or reccurrent pancreatic cancer and biliary cancer (20 patients)
Registration Number
JPRN-UMIN000004525
Lead Sponsor
Department of surgery, Tokushima university hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

(1) The patients have severe organ disorder. (2) The patients have more than 2.5 times of AST or ALT. (3) The patients have more than 2mg/dl of Total-Bilirubin. (4) The patients have more than 5mg/dl of Creatinin. (5) The patients have less than 90% of SaO2. (6) The patients have severe organ complication. (7) The patiens have allergy. (8) The patients have agressive duplication cancer. (9) The patients is considered unaddaptive.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
tumor marker and tumor size
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath